ADC Therapeutics SA

1
NYSE:ADCT (Switzerland)  
$ 4.34 -0.1 (-2.25%) 10:08 PM EST
At Loss
Market Cap:
$ 358.18M
Enterprise V:
$ 212.21M
Volume:
322.94K
Avg Vol (2M):
542.68K
Volume:
322.94K
At Loss
Avg Vol (2M):
542.68K

Business Description

Description
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
Name Current Vs Industry Vs History
Cash-To-Debt 2.24
Equity-to-Asset -0.42
Debt-to-Equity -0.84
Debt-to-EBITDA -0.86
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -5.11
Distress
Grey
Safe
Beneish M-Score -5.38
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 21.3
3-Year EPS without NRI Growth Rate 2.3
3-Year FCF Growth Rate 17.1
Name Current Vs Industry Vs History
5-Day RSI 31.83
9-Day RSI 40.41
14-Day RSI 44.83
6-1 Month Momentum % 564.22
12-1 Month Momentum % 121.94

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.97
Quick Ratio 4.73
Cash Ratio 4.12
Days Inventory 2559.07
Days Sales Outstanding 175.51
Days Payable 1653.45

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2.4
Shareholder Yield % -3.72
Name Current Vs Industry Vs History
Gross Margin % 96.36
Operating Margin % -237.29
Net Margin % -345.11
FCF Margin % -175.25
ROA % -52.47
ROIC % -160.49
ROC (Joel Greenblatt) % -687.66
ROCE % -39.13

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 5.19
EV-to-EBIT -1.43
EV-to-EBITDA -1.46
EV-to-Revenue 3.05
EV-to-Forward-Revenue 2.75
EV-to-FCF -1.74
Earnings Yield (Greenblatt) % -69.93
FCF Yield % -34.03

Financials (Next Earnings Date:2024-05-09 Est.)

ADCT's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NYSE:ADCT

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

ADC Therapeutics SA Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 69.558
EPS (TTM) ($) -2.95
Beta 1.69
Volatility % 153.93
14-Day RSI 44.83
14-Day ATR ($) 0.383907
20-Day SMA ($) 4.65
12-1 Month Momentum % 121.94
52-Week Range ($) 0.35991 - 6.04
Shares Outstanding (Mil) 82.53

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

ADC Therapeutics SA Filings

Filing Date Document Date Form
No Filing Data

ADC Therapeutics SA Stock Events

Financials Calendars
Event Date Price($)
No Event Data

ADC Therapeutics SA Frequently Asked Questions

What is ADC Therapeutics SA(ADCT)'s stock price today?
The current price of ADCT is $4.34. The 52 week high of ADCT is $6.04 and 52 week low is $0.36.
When is next earnings date of ADC Therapeutics SA(ADCT)?
The next earnings date of ADC Therapeutics SA(ADCT) is 2024-05-09 Est..
Does ADC Therapeutics SA(ADCT) pay dividends? If so, how much?
ADC Therapeutics SA(ADCT) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1